(SGMO) Sangamo Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SGMO) Sangamo Therapeutics, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Sangamo Therapeutics, Inc. BCG Matrix is a ready-made strategic tool used to assess the company’s products or business units across the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
SB-525 hemophilia A Phase III AFFINE
SB-525 in Phase III AFFINE is Sangamo Therapeutics, Inc.'s most advanced hemophilia A asset, and that matters in a market that treats about 1 in 5,000 male births. Hemophilia A is a high-value rare-disease space with long-term factor VIII demand, and Phase III gives SB-525 the clearest path to commercial scale if efficacy and safety hold.
ST-920 Fabry disease Phase I/II STAAR
ST-920 is Sangamo Therapeutics, Inc.’s Phase I/II gene therapy for Fabry disease, a rare X-linked disorder seen in about 1 in 40,000 males. If durability and safety hold, a one-time therapy could capture high value per patient versus chronic enzyme replacement that can cost hundreds of thousands of dollars a year. That makes ST-920 one of Sangamo Therapeutics, Inc.’s key upside assets in the Stars quadrant.
SAR445136 sickle cell disease Phase I/II PRECIZN-1
SAR445136 in Phase I/II PRECIZN-1 targets sickle cell disease, a global market with over 8 million people affected and deep unmet need. The gene and cell therapy field still earns a high innovation premium, especially for curative data. If Sangamo Therapeutics, Inc. posts clean efficacy and safety readouts, this asset could move from pipeline risk to major value driver.
ZFP genome editing platform
Sangamo Therapeutics, Inc.’s zinc finger protein platform is its core asset, because it can drive both precise gene editing and gene regulation across multiple targets. That breadth gives the company more than one shot at value creation, instead of depending on a single drug candidate.
- Core platform, not one asset
- Enables editing and regulation
- Supports multiple target programs
- Creates leverage across the pipeline
ZFP transcription-factor platform
Sangamo Therapeutics, Inc.'s ZFP transcription-factor platform can turn genes up or down without cutting DNA, which keeps it distinct from pure gene-editing tools. That matters in hard-to-treat diseases where dose control and reversibility can be valuable. In a genomic-medicine market still expanding fast, this platform remains a Star candidate.
- Modulates expression, not DNA sequence.
- Supports hard-to-treat disease programs.
- Stays differentiated in genomic medicine.
Sangamo’s Star Assets: SB-525, ST-920, and SAR445136
Stars in Sangamo Therapeutics, Inc. are SB-525, ST-920, and SAR445136. SB-525 is in Phase III, the clearest near-term value driver; ST-920 is in Phase I/II with one-time therapy upside in Fabry disease; SAR445136 targets sickle cell disease in a large unmet market. Together, these programs keep Sangamo Therapeutics, Inc. tied to high-value rare-disease growth.
| Asset | Stage | Why Star |
|---|---|---|
| SB-525 | Phase III | Lead hemophilia A value |
| ST-920 | Phase I/II | Fabry upside |
What is included in the product
Detailed Word Document
Sangamo Therapeutics BCG Matrix maps its pipeline by growth and share, showing where to invest, hold, or divest.
Editable Excel File
One-page Sangamo Therapeutics BCG Matrix for quick quadrant clarity and easier decision-making
Reference Sources
Provides a credible source trail for Sangamo Therapeutics, making the analysis easier to verify, trust, and use in decisions.
Cash Cows
Biogen MA collaboration
Biogen MA collaboration gives Sangamo an external cash stream with low selling cost, since partner-led deals can pay upfront fees, research funding, and milestones. That fits a cash-cow style for a pre-revenue biotech: recurring partner cash can support R&D without building a big sales force. The key risk is that revenue depends on Biogen’s program progress and deal terms, not owned product sales.
Sanofi collaboration
Sanofi is one of Sangamo Therapeutics, Inc.’s longest-running pharma partners, and deals like this can fund R&D without new share issuance. In Sangamo Therapeutics, Inc.’s 2025 filings, collaboration revenue from big partners remained a key cash source, with milestone-linked payments tied to development progress. That steady, non-dilutive cash helps support the core pipeline.
Pfizer collaboration
Pfizer gave Sangamo access to big-pharma hemophilia gene therapy resources, which helped fund work even when a program was not headed to market. In BCG terms, that made the tie a Cash Cow: low growth, but steady value through research support and milestone income. Sangamo kept monetizing the deal structure in 2025 while sharing risk with a much larger partner.
Novartis collaboration
Novartis is one of Sangamo Therapeutics, Inc.'s most mature partner ties, and the nearest fit to a cash cow in the mix. The deal structure was mainly low-capital partner funding, with historical terms of up to $300 million in milestones plus royalties, versus building fully funded internal programs.
That makes it a steadier, less risky revenue channel than early-stage R&D bets.
- Major partner, mature economics
- Upfront and milestone-driven cash flow
- Lower capital needs than in-house programs
Kite, Genentech, Roche and other licensing deals
Kite, Genentech, Roche, and similar licensing deals give Sangamo access to large pharma platforms, so its gene-regulation tech can scale without a full sales force. These agreements can bring milestone and royalty income, which is steadier than clinical-stage product bets. In BCG terms, this is the most reliable cash engine in the mix.
- Large pharma ecosystems widen reach
- Milestones and royalties can recur
- Cash flow is steadier than pipeline bets
Biogen, Sanofi, Pfizer Drive Sangamo’s Cash Engine
Biogen MA, Sanofi, Pfizer, Novartis, and Roche/Kite deals are Sangamo Therapeutics, Inc.’s closest Cash Cows: partner-led funding, low selling cost, and non-dilutive cash. In 2025 filings, collaboration revenue stayed the main cash source, which helped fund R&D without a large sales force. The tradeoff is clear: cash depends on partner milestones and program progress.
| Cash cow lever | 2025 role |
|---|---|
| Partner funding | Main cash source |
| Sales cost | Low |
Full Version Awaits
Sangamo Therapeutics, Inc. Reference Sources
You’re previewing the exact Sangamo Therapeutics, Inc. BCG Matrix document you’ll receive after purchase. No placeholder content or watermarks—just the complete, professionally formatted file. It’s ready for immediate use in analysis, presentation, or strategic planning. What you see here is what you get.
Dogs
No marketed product
Sangamo Therapeutics, Inc. remained clinical-stage through end-2025 and reported no approved therapy, so it had no durable product sales to classify as a commercial Dog. Its 2025 revenue was still driven by collaboration and milestone income, not marketed products, which means there was no legacy cash cow to harvest. In BCG terms, the Dog bucket is effectively empty here because there is no commercial asset to divest or redeploy.
High R&D burn
Sangamo Therapeutics, Inc. still carries a high R&D burn because most of its gene therapy and genome-editing programs remain in development, so cash goes out faster than revenue comes in. That makes the portfolio expensive to carry, and any program that does not move quickly into the clinic or partnership stage can turn into a cash trap. In BCG terms, this is a clear Dog: weak cash generation, heavy spend, and limited near-term payback.
Minimal commercial infrastructure
Sangamo Therapeutics keeps a lean commercial setup, with no large marketed-product sales force, so fixed selling costs stay low. In FY2025, that meant there was no mature revenue base to spread overhead across; weak programs therefore had little operating leverage. For a BCG Dogs view, that points to low scale and limited cash pull from commercial execution.
Dependence on external financing
Sangamo Therapeutics, Inc. is a classic Dog risk: clinical-stage biotech depends on capital raises, partner cash, and milestone payments, so tight markets can squeeze the weakest programs first. If funding costs rise or deal flow slows, low-return assets are the first to get cut or delayed.
- Capital access drives pipeline survival.
- Weak funding pressures marginal programs.
Volatile collaboration revenue
Sangamo Therapeutics, Inc. still depends on partner income that can swing quarter to quarter, so a slipped milestone can cut revenue visibility fast. In BCG terms, that makes stalled Dogs hard to defend, because the cash they bring in is uneven and tied to deal timing, not steady demand.
- Milestones drive lumpy revenue
- Delays weaken forecast visibility
- Weak assets merit low capital
Sangamo’s Empty Dog Bucket: No Sales, High Burn, Little Near-Term Payoff
Sangamo Therapeutics, Inc. had no approved therapy in FY2025, so its Dogs bucket was effectively empty: no durable product sales, no cash cow, and no asset to harvest. Revenue still came from collaboration and milestone income, while R&D burn stayed high, so weak programs tied up cash with little near-term payoff. That makes any stalled asset a low-return Dog, especially if partner timing slips.
| Dog signal | FY2025 fact |
|---|---|
| Product sales | None |
| Revenue mix | Collaboration and milestones |
| Commercial scale | No marketed product base |
Question Marks
TX200 HLA-A2 kidney transplant rejection
TX200 targets kidney transplant rejection, a high-value area because rejection still drives graft loss and long-term drug use. The market is attractive, but Sangamo Therapeutics, Inc. has not yet shown clear clinical or commercial differentiation for TX200, so market share is still unproven. That makes it a classic Question Mark: upside is real, but execution risk is high.
KITE-037 cancer cell therapy
KITE-037 sits in a fast-growing but crowded cancer cell therapy market, where the FDA had cleared 40+ cell and gene therapies by 2025. Sangamo has an entry, but no proven commercial share or approved product here, so it is a classic question mark. The asset needs clear clinical wins and funding discipline to move from optionality to scale.
ST-501 tauopathies
ST-501 sits in a high-need tauopathy field where no approved disease-modifying tau-targeting therapy has yet changed care, so the upside is real but unproven.
The program is still early, and neuroscience assets often need 7-10 years plus large, costly trials before they can justify major capital.
For Sangamo Therapeutics, Inc., ST-501 is a Question Mark: it needs stronger human data and clear biomarker proof before it can earn a bigger investment.
ST-502 synucleinopathies
ST-502 sits in Question Mark territory because synucleinopathies, led by Parkinson's disease, are huge unmet-need markets, but Sangamo Therapeutics, Inc.'s program is still early and small versus the field. Parkinson's affects more than 10 million people worldwide, yet disease-modifying options remain limited, so the prize is big if the data readout improves.
- Large market, low share.
- Early-stage asset, high R&D risk.
- Upside depends on clinical proof.
Next-generation CNS and neuromuscular programs
Sangamo Therapeutics, Inc.'s next-generation CNS and neuromuscular programs are classic question marks: big markets, high unmet need, but long Phase 1-3 timelines and heavy capital use. ALS affects about 30,000 Americans, and Duchenne muscular dystrophy hits roughly 1 in 3,500-5,000 male births, so any clean data can move value fast. If efficacy and safety hold, they can shift to stars; if not, they can end up as dogs.
- High unmet need, high upside
- Long trials, high cash burn
- Data win means star potential
- Weak data means dog risk
Sangamo’s Pipeline: Big Markets, Early Data, High Risk
Sangamo Therapeutics, Inc.’s Question Marks have big markets but no proven share yet. TX200, KITE-037, ST-501, and ST-502 all need clinical wins, and the cash burn is still heavy while value stays tied to trial data.
| Program | Signal | Market cue |
|---|---|---|
| TX200 | Early | Kidney rejection |
| KITE-037 | Unproven | 40+ approved CGTs by 2025 |
| ST-501 | Early | Tauopathy no approved therapy |
| ST-502 | Early | Parkinson’s affects 10M+ worldwide |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.